ESR1 and breast cancer: Results showed that patients who were previously diagnosed with ER+/PR+ breast cancer and had presented with metastatic recurrence, harbored between 40 and 60% CTCs that did not correspond to the hormone receptor status of the primary tumor (Supplementary Fig. 8a).